PriceTargets.com logo

Exscientia - EXAI Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.00
  • Forecasted Upside: 44.63%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.84 As of 11/20/2024 09:00 PM ET
▲ +0.15 (3.20%)

This chart shows the closing price for EXAI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Exscientia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EXAI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXAI

Analyst Price Target is $7.00
▲ +44.63% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Exscientia in the last 3 months. The average price target is $7.00, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 44.63% upside from the last price of $4.84.

This chart shows the closing price for EXAI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 polled investment analysts is to hold stock in Exscientia. This rating has held steady since July 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/13/2024BarclaysReiterated RatingOverweight ➝ Equal Weight$5.00
8/9/2024TD CowenReiterated RatingBuy ➝ Hold
7/29/2024BarclaysLower TargetOverweight ➝ Overweight$10.00 ➝ $9.00
7/9/2024TD CowenInitiated CoverageBuy
4/22/2024Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$7.00 ➝ $7.00
1/5/2024Bank of AmericaDowngradeBuy ➝ Neutral$11.00 ➝ $9.00
10/17/2023BarclaysLower TargetOverweight ➝ Overweight$12.00 ➝ $10.00
10/11/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $7.00
10/4/2023Bank of AmericaLower Target$16.00 ➝ $11.00
7/31/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$14.00
7/21/2023Berenberg BankInitiated CoverageBuy$13.00
7/20/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$14.00
4/10/2023Morgan StanleyLower TargetEqual Weight$15.00 ➝ $14.00
11/16/2022BarclaysLower TargetOverweight$40.00 ➝ $12.00
9/9/2022Morgan StanleyLower TargetEqual Weight$18.00 ➝ $15.00
8/24/2022Morgan StanleyLower TargetEqual Weight$20.00 ➝ $18.00
6/13/2022Morgan StanleyLower TargetEqual Weight$21.00 ➝ $20.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$23.00 ➝ $20.00
4/11/2022Morgan StanleyBoost TargetEqual Weight$20.00 ➝ $21.00
10/26/2021Bank of AmericaInitiated CoverageBuy$27.00
10/26/2021Morgan StanleyInitiated CoverageEqual Weight$25.00
10/26/2021The Goldman Sachs GroupInitiated CoverageBuy$30.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 60 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 3 very positive mentions
  • 74 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 3 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Exscientia logo
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: $4.84
Low: $4.49
High: $4.85

50 Day Range

MA: $5.00
Low: $4.69
High: $5.96

52 Week Range

Now: $4.84
Low: $3.80
High: $7.91

Volume

1,510,000 shs

Average Volume

657,833 shs

Market Capitalization

$632.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Exscientia?

The following Wall Street research analysts have issued research reports on Exscientia in the last twelve months: Bank of America Co., Barclays PLC, Morgan Stanley, and TD Cowen.
View the latest analyst ratings for EXAI.

What is the current price target for Exscientia?

0 Wall Street analysts have set twelve-month price targets for Exscientia in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 44.6%. Bank of America Co. has the highest price target set, predicting EXAI will reach $9.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $5.00 for Exscientia in the next year.
View the latest price targets for EXAI.

What is the current consensus analyst rating for Exscientia?

Exscientia currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EXAI, but not buy more shares or sell existing shares.
View the latest ratings for EXAI.

What other companies compete with Exscientia?

Other companies that are similar to Exscientia include Protagonist Therapeutics, Agios Pharmaceuticals, Iovance Biotherapeutics, Amneal Pharmaceuticals and Longboard Pharmaceuticals. Learn More about companies similar to Exscientia.

How do I contact Exscientia's investor relations team?

The company's listed phone number is 44-0-18-6581-8941 and its investor relations email address is [email protected]. The official website for Exscientia is www.exscientia.ai. Learn More about contacing Exscientia investor relations.